Biotechnology

Medicus Pharma

Medicus Pharma and Reliant AI Sign Intent to Develop AI Platform for Clinical Trials

Medicus Pharma released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.9728

Medicus Pharma released FY2025 Q3 earnings on November 14, 2025, EST: Actual Revenue USD 0 (Forecast USD 0), Actual EPS USD -1.1236 (Forecast USD -0.34)

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Medicus Pharma released FY2024 Q2 earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -0.4447

Medicus Pharma released FY2024 Q3 earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -0.311

Medicus Pharma released FY2024 9 Months Earnings on August 12, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.8956

Medicus Pharma released FY2024 Semi-Annual earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -0.6574

Medicus Pharma released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -0.4323

Medicus Pharma released FY2025 Semi-Annual earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -0.8141

Medicus Pharma Submits Type C Meeting Request to FDA

Medicus Pharma Acquires Antev Ltd.

Medicus Pharma Ltd. Appoints Andrew Smith as COO

Medicus Pharma Ltd. reaches $5 million bond agreement with Yorkville

Medicus Pharma Plans to Acquire Antev Ltd.

Medicus Pharma Submits Development Plan for MNA Patch for Treatment of Equine SCC to FDA

Medicus Pharma Ltd. Issued Stocks to Raise Funds for Clinical Trials

Medicus Pharma Files to Resell Up to 3.7M Ordinary Shares

D. Boral Capital Maintains Medicus Pharma Buy Rating

Medicus Receives UAE Health Ministry Approval for Skin Cancer Phase II Study

Urban-Gro

Mill City Ventures III

Real Messenger

Next Tech

MKD Tech

Tradr 2X Long SRPT Daily ETF

NEUBERGER HIGH YLD STRATEGIES FD COM USD0.0001 (S/R 15/04/2026) WI

iTonic

Aspire Biopharma

Paysign

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Medicus Pharma(MDCX.US)

Medicus Pharma Stock Performance Chart